Solvay Q1 Operating Tops Forecast

Solvay posted a 53 % fall in recurring Q1 operating profit, beating estimates, but said full-year operating profit would be below 2008. Recurring earnings before interest and tax (REBIT) fell to €142 million. Last year, the company reported €300 million in Q1 REBIT. Solvay said the pharmaceuticals unit would achieve in 2009 a higher operating result than last year, but conditions remained difficult for chemicals and plastics and visibility was limited.

Register now!

The latest information directly via newsletter.

To prevent automated spam submissions leave this field empty.